Bayer updates press on current pipeline

12 January 2009

Germany-based Bayer Healthcare's head of pharmaceuticals, Wolfgang Plischke, updated journalists from 22 countries on the firm's pipeline  at its Perspective on Innovation 2008 conference held at the BayKomm  exhibition center in Leverkusen (Marketletter Decemeber 22).

Noting recent developments, Dr Plischke said that Yaz Plus, the new  formulation of Yasmin (drospirenone/ethinyl estradiol) was due to launch  in 2010. He also explained that a wet age-related macular degeneration  product had entered Phase III, following promising Phase II results.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight